This was consistent with studies in this laboratory showing that CDDO-Me induced ROS and ROS-dependent downregulation of Sp1, Sp3 and Sp4 and pro-oncogenic Sp-regulated genes and has been observed with other ROS-inducing anticancer agents in pancreatic cancer cells [42–44]. The gene discussed is SP4; the disease is familial pancreatic carcinoma.